Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https://doi.org/10.1038/s41572-020-00240-3

Article  PubMed  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A (2022) Hepatocellular carcinoma. Lancet 400:1345–1362. https://doi.org/10.1016/S0140-6736(22)01200-4

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19:151–172. https://doi.org/10.1038/s41571-021-00573-2

Article  CAS  PubMed  Google Scholar 

El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905. https://doi.org/10.1056/NEJMoa1915745

Article  CAS  PubMed  Google Scholar 

Finn RS, Ikeda M, Zhu AX et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38:2960–2970. https://doi.org/10.1200/JCO.20.00808

Article  PubMed  PubMed Central  Google Scholar 

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. https://doi.org/10.1056/NEJMoa021423

Article  PubMed  Google Scholar 

Mayr R, Gierth M, Zeman F et al (2018) Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle 9:505–513. https://doi.org/10.1002/jcsm.12279

Article  PubMed  PubMed Central  Google Scholar 

Dolan RD, Almasaudi AS, Dieu LB, Horgan PG, McSorley ST, McMillan DC (2019) The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. J Cachexia Sarcopenia Muscle 10:111–122. https://doi.org/10.1002/jcsm.12357

Article  PubMed  Google Scholar 

Lee JH, Yoon YC, Kim HS et al (2022) Obesity is associated with improved postoperative overall survival, independent of skeletal muscle mass in lung adenocarcinoma. J Cachexia Sarcopenia Muscle 13:1076–1086. https://doi.org/10.1002/jcsm.12956

Article  PubMed  PubMed Central  Google Scholar 

Fujiwara N, Nakagawa H, Kudo Y et al (2015) Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63:131–140. https://doi.org/10.1016/j.jhep.2015.02.031

Article  CAS  PubMed  Google Scholar 

Ahima RS, Lazar MA (2013) Physiology. The health risk of obesity–better metrics imperative. Science 341:856–858. https://doi.org/10.1126/science.1241244

Article  CAS  PubMed  Google Scholar 

Takenaka Y, Oya R, Takemoto N, Inohara H (2021) Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle 12:1122–1135. https://doi.org/10.1002/jcsm.12755

Article  PubMed  PubMed Central  Google Scholar 

Young AC, Quach HT, Song H et al (2020) Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J Immunother Cancer 8:821. https://doi.org/10.1136/jitc-2020-000821

Article  Google Scholar 

Chen BB, Liang PC, Shih TT et al (2023) Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol 33:512–522. https://doi.org/10.1007/s00330-022-08980-4

Article  CAS  PubMed  Google Scholar 

Akce M, Liu Y, Zakka K et al (2021) Impact of Sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody. Am J Clin Oncol 44:74–81. https://doi.org/10.1097/COC.0000000000000787

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380. https://doi.org/10.1002/hep.29086

Article  PubMed  Google Scholar 

Hiraoka A, Michitaka K, Ueki H et al (2016) Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease. Eur J Gastroenterol Hepatol 28:940–947. https://doi.org/10.1097/MEG.0000000000000661

Article  PubMed  Google Scholar 

Kim N, Yu JI, Park HC et al (2021) Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 70:1593–1603. https://doi.org/10.1007/s00262-020-02794-3

Article  CAS  PubMed  Google Scholar 

Matsumoto H, Tsuchiya K, Nakanishi H et al (2022) Clinical usefulness of monitoring muscle volume during atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma. Cancers (Basel) 14:551. https://doi.org/10.3390/cancers14143551

Article  CAS  Google Scholar 

Stretch C, Aubin JM, Mickiewicz B et al (2018) Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. PLoS ONE 13:e0196235. https://doi.org/10.1371/journal.pone.0196235

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams GR, Deal AM, Muss HB et al (2017) Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia. Oncotarget 8:33658–33665. https://doi.org/10.18632/oncotarget.16866

Article  PubMed  PubMed Central  Google Scholar 

Chu MP, Li Y, Ghosh S et al (2020) Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J Cachexia Sarcopenia Muscle 11:748–755. https://doi.org/10.1002/jcsm.12538

Article  PubMed  PubMed Central  Google Scholar 

Waldmann TA, Dubois S, Miljkovic MD, Conlon KC (2020) IL-15 in the combination immunotherapy of cancer. Front Immunol 11:868. https://doi.org/10.3389/fimmu.2020.00868

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA (2010) Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 16:6019–6028. https://doi.org/10.1158/1078-0432.CCR-10-1966

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo Y, Ren Y, Wu F, Dong X, Zheng C (2022) Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therap Adv Gastroenterol 15:17562848221142416. https://doi.org/10.1177/17562848221142417

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tenuta M, Gelibter A, Pandozzi C et al (2021) Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective Study. Cancers (Basel) 13:355. https://doi.org/10.3390/cancers13246355

Article  CAS  Google Scholar 

Lee JH, Hyung S, Lee J, Choi SH (2022) Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. J Immunother Cancer 10:226. https://doi.org/10.1136/jitc-2022-005226

Article  Google Scholar 

Sanchez A, Furberg H, Kuo F et al (2020) Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol 21:283–293. https://doi.org/10.1016/S1470-2045(19)30797-1